FDA grants accelerated approval to GSK’s Jemperli for MSI‑H/dMMR locally advanced rectal cancer
The U.S. Food and Drug Administration approved Jemperli (dostarlimab‑gxly) under an accelerated pathway for adults with stage II‑III MSI‑H/dMMR locally advanced rectal cancer. The decision relied on the phase II AZUR‑1 trial, which showed that a substantial share of patients achieved a sustained clinical complete response at 12 months. GSK said the immunotherapy could let eligible patients avoid chemotherapy, radiation and surgery, offering a more personalized treatment option.
Why it matters
The approval adds a new indication to Jemperli, creating a potential revenue stream for GSK in a biomarker‑defined subset of rectal cancer patients (about 5‑10% of cases). The label expansion also benefits partner AnaptysBio, which co‑develops the drug, by increasing its commercial exposure.
Key facts
- 1The FDA granted accelerated approval on 19 Oct 2026 for adults with stage II‑III MSI‑H/dMMR locally advanced rectal cancer. oncnursingnews.com
- 2In the AZUR‑1 trial, 47 % of independent‑review‑evaluable patients reached a 12‑month clinical complete response (cCR12). oncnursingnews.com
- 3Investigator‑assessed data showed 68 % of evaluable patients achieved cCR12. oncnursingnews.com
- 4An exploratory analysis reported that 76 % of evaluable patients had no detectable cancer after at least one year of follow‑up. us.gsk.com
- 5Serious adverse reactions occurred in 20 % of patients; the most common were fatigue (32 %), rash (22 %), diarrhea (18 %) and pruritus (17 %). us.gsk.com
- 6The drug received Fast Track, Breakthrough Therapy, Priority Review and a National Priority Voucher, enabling accelerated approval ahead of the PDUFA date. us.gsk.com
Summary written by AlphAI AI Desk from 20 of 27 sources. Not investment advice. Figures are as stated by the linked sources.